The global biotherapeutics cell line development market is characterized by a largely consolidated landscape, as the top two players held a sizeable share of 85% of the global market in 2015, finds Transparency Market Research (TMR). These companies are Beckman Coulter and Becton Dickinson and Company. The combined massive share held by these players is increasingly inhibiting the entry of new players, for whom the merger may be a potential option for getting a foothold in the market. The significant clout that leading players hold in the market accounts for the plethora of avenues to organically boost their expansion and consolidate their shares. TMR observes that over the years, several emerging and new entrants are likely to focus on new product developments and technological innovations to get a better foothold in the market.
Some of the other prominent players operating in the market include Thermo Fisher Scientific Inc., ProBioGen AG, Boehringer Ingelheim, Sony Biotechnology Inc., Sysmex Partec GmbH, Lonza Group Ltd., CMC Biologics, Catalent Inc., and Beckman Coulter.The global biotherapeutics cell line development market stood at US$56 million in 2014 and is projected to touch a valuation of approximately US$100 million by the end of 2022. The market is prognosticated to expand at 7.50% CAGR in between the forecast period from 2015 to 2022.
Request A Sample-
The main processes of biotherapeutics cell line development comprise transfection and selection and single cell cloning. Of the two, the former led the majority of the share by a huge margin in 2015. This can be attributed to the extensive application of the various methods of single cell cloning in proving the monoclonality during cell line development.
Regionally, Asia Pacific is projected to emerge as the potentially attractive market rising at a promisingly higher CAGR pegged at 9.40% during 2015–2022. The colossal untapped medical needs is key to the rapid rise of the regional revenue.